Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286974 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01286974 is a Phase 1 study that was terminated before completion, run by Abbott. The registered enrollment target is 3 participants.
The verdict
NCT01286974, a Phase 1 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.
Interventions
- DRUG [14C]linifanib
- DRUG ABT-869, linifanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01286974
The ClinicalTrials.gov registry entry for NCT01286974 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [14C]linifanib is the first listed.
NCT01286974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01286974 about?
NCT01286974 is a clinical study titled "A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.". A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.
What is the current status of trial NCT01286974?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01286974?
The interventions under investigation include: [14C]linifanib (DRUG), ABT-869, linifanib (DRUG).
Who is sponsoring clinical trial NCT01286974?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.